Feature | May 15, 2015

ECG Sensors on Smartphones Detect Atrial Fibrillation in the General Adult Public

Large study using the latest body-worn sensors for health tracking found to increase awareness of heart rate and behavior presented at Heart Rhythm 2015

HRS, ECG, smartphones, atrial fibrillation, AF, Heart Rhythm 2015

May 15, 2015 — A new, large-scale study has found adding an electrocardiogram (ECG) to the latest generation of body-worn sensors accurately detects atrial fibrillation (AF) and significantly increases awareness of heart rate and behavior. Body-worn or wearable wireless sensors are increasingly being used to help collect health-related information that can be shared with a doctor through a smartphone application. The study results show that by using ECG sensors with a smartphone application, the general adult population can efficiently track their heart rate data. The new findings were presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.

More than 36 million Americans currently use body-worn sensors for activity and heart rate tracking and the trend is on the rise. This population is expected to grow to 135 million by 2018. Additionally, AF, the most common heart arrhythmia, affects more than 2.7 million American adults and its presence is increasing rapidly. In the next 30-40 years, the number of people diagnosed with AF in the United States is expected to more than double. This increased access to heart rhythm data will be even more important as the prevalence of AF grows.

Study participants were provided with a smartphone-enabled ECG sensor from AliveCor and had their ECG and heart rate data evaluated over a six-month period. The device records a 30-second ECG and wirelessly transmits the recording to a secure cloud-based server. Participants were also asked to download a mobile software application that facilitated ECG acquisition and access to ECG interpretation.

More than 800 study participants transmitted 57,703 ECGs during the six-month period. Chronic health conditions were reported by 113 participants and only 21 participants were taking any medication. AF was detected in 185 recordings in 93 unique subjects (11 percent). After 30 days of use, the majority of participants (73 percent) stated they were more aware of their heart rate and behavior.

“Having an ECG device on smartphones is quite incredible because it makes tracking heart health and behavior accessible to almost anyone. The experience of using an ECG device through a smartphone creates opportunities for people to truly pay attention and understand their heart rhythm,” said lead author Leslie A. Saxon, M.D., executive director of the University of Southern California Center for Body Computing. “Not only does using these type of smartphone apps allow the patient to be more informed, but it also allows their physician the ability to access and analyze real-world data which can ultimately help improve treatment and overall quality of care.”

As use of body-worn sensors and health tracking smartphone applications increases, the ability to chronicle and store the population’s ECGs will lead to greater understanding of cardiac behavior and heart rhythm disorders like AF. Heart rhythm is dynamic and the portability and wireless connectivity of smartphone-enabled ECG devices will provide unprecedented public access to screening, diagnostic and monitoring data.

For more information: www.hrsonline.org

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init